Romiplostim

Source: Wikipedia, the free encyclopedia.

Romiplostim
Clinical data
Trade namesNplate, Romiplate
Other namesAMG531
AHFS/Drugs.comMonograph
MedlinePlusa609008
License data
Pregnancy
category
  • AU: B3
Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Elimination half-life1 to 34 days
Identifiers
  • L-methionyl[human immunoglobulin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7′:10,10′)-bisdisulfide dimer
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2634H4086N722O790S18
Molar mass59085.01 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.

The drug was developed by Amgen through a restricted usage program called NEXUS.[1] During development and clinical trials the drug was called AMG531.[2]

Medical uses

Romiplostim is indicated as a potential treatment for

U.S. Food and Drug Administration (FDA) in 2003, as the chronic ITP population in the USA is under 200,000 (the chronic adult ITP population in the USA is thought to be around 60,000, with women outnumbering men by a factor of two).[4] The wholesale cost of romiplostim if administered weekly is currently estimated at US$55,250 per year.[5]

On August 22, 2008, the FDA approved romiplostim as a long-term treatment for chronic ITP in adults who have not responded to other treatments, such as

intravenous immunoglobulin, Rho(D) immune globulin or splenectomy.[1][6]

Clinical efficacy

In well designed, 24-week, Phase III trials, romiplostim was significantly more effective than placebo in achieving the primary endpoint of a protocol-defined durable platelet response in nonsplenectomized or splenectomized adults with chronic immune thrombocytopenic purpura.[7]

Side-effects

Romiplostim's effect is to stimulate the patient's

red blood count, and thus death.[citation needed
]

Experimental treatment of acute radiation syndrome

Romiplostim may be used to treat acute radiation syndrome.[8] "To reduce radiation-induced bleeding, Nplate stimulates the body’s production of platelets. The drug can be used to treat adults and children."[8]

References

  1. ^ a b Waknine Y (4 September 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. Retrieved 4 September 2008. Freely available with registration.
  2. PMID 17050891
    .
  3. S2CID 23827197
    .
  4. ^ "Amgen to Discuss Romiplostim BLA". drugs.com. 12 March 2008. Retrieved 4 November 2008.
  5. PMID 19386944
    .
  6. ^ "FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP" (Press release). Amgen. 22 August 2008. Archived from the original on 15 September 2008. Retrieved 4 September 2008.
  7. PMID 19275274
    .
  8. ^ a b Roberts L (5 October 2022). "US splashes $290m on anti-radiation drugs after Putin ups nuclear threats". The Daily Telegraph. Retrieved 10 October 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Romiplostim&oldid=1215777805"